Generated by AI
Caris Life Sciences, Inc. is a precision medicine and diagnostic technology company focused on applying comprehensive molecular information and artificial intelligence to healthcare. Its current services include molecular profiling, genomic and diagnostic testing, and anatomic pathology solutions that help characterize disease at the patient level. The company’s platforms support biomarker discovery, treatment selection, disease monitoring, clinical research, and the identification of potential therapeutic targets. Caris Life Sciences, Inc. primarily serves oncology, where detailed tumor analysis can inform personalized care, while also supporting academic institutions, healthcare providers, and biopharmaceutical companies. Its capabilities combine laboratory diagnostics, bioinformatics, data analysis, and machine-learning tools to organize complex biological information for clinical and research applications. By connecting diagnostic services with drug development and precision medicine workflows, Caris Life Sciences, Inc. occupies a specialized role at the intersection of life sciences, artificial intelligence, laboratory medicine, and biopharmaceutical innovation. The company’s offerings contribute to the use of molecular data in modern disease management and therapeutic development.
Website750 West John Carpenter Freeway
Irving, TX, 75039
United States
The latest articles about CAI.
Caris Life Sciences Inc (CAI) posted 27% revenue growth to a record $275.4 million, returned to GAAP profitability, and lifted its 2026 revenue outlook to roughly $1.04 billion to $1.05 billion.
Summary of Oct 28's posts. Generated by AI.
Summary of Jan 2's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about CAI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.